Benitec Biopharma
BNTC
7 hedge funds and large institutions have $186K invested in Benitec Biopharma in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
82% less capital invested
Capital invested by funds: $1.05M → $186K (-$860K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$51.9K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$20.7K |
| 3 |
Morgan Stanley
New York
|
+$9.73K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.49K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$527K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$127K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $55K | +$4.87K | +12 | +4% |
|
|
2
Morgan Stanley
New York
| $53K | +$9.73K | +24 | +10% |
|
|
SFM
3
Sphera Funds Management
Tel Aviv,
Israel
| $30K | -$127K | -314 | -67% |
|
|
4
Citadel Advisors
Miami,
Florida
| $24K | +$51.9K | +128 | New |
|
5
Renaissance Technologies
New York
| $10K | – | – | – |
|
|
OMC
6
Old Mission Capital
Chicago,
Illinois
| $10K | +$20.7K | +51 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $4K | +$6.49K | +16 | +267% |
|
|
HCM
8
Highbridge Capital Management
New York
| – | -$527K | -1,055 | Closed |
|
BNTC Hedge Fund Activity: Q2 2019 in Review
7 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2019, worth a combined $186K — down 82% from $1.05M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BNTC positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $51.9K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $527K sold.
- 7 institutional investors held Benitec Biopharma (BNTC) as of Q2 2019, up from 6 in Q1 2019.
- Funds reported $186K of Benitec Biopharma stock for Q2 2019, down 82% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q2 2019 and 1 closed out, a net change of +1 holder.
- The largest Benitec Biopharma buyer in Q2 2019 was Citadel Advisors, an estimated $51.9K added.
- The largest Benitec Biopharma seller in Q2 2019 was Highbridge Capital Management, an estimated $527K sold.
Based on aggregated 13F filings for Q2 2019.